Announcements
- Karolinska Development invests in BOOST Pharma, expanding its portfolio
- Karolinska Development breddar sin portfölj genom nyinvestering i BOOST Pharma
- Karolinska Developments årsstämma 2024
- Karolinska Development’s Annual General Meeting 2024
- Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC
- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
- Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
- Notice of Annual General Meeting in Karolinska Development AB (publ)
More ▼
Key statistics
On Friday, Karolinska Development AB (2I9:MUN) closed at 0.1312, 5.98% above its 52-week low of 0.1238, set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1312 |
---|---|
High | 0.1312 |
Low | 0.1312 |
Bid | 0.1252 |
Offer | 0.1424 |
Previous close | 0.1312 |
Average volume | 880.00 |
---|---|
Shares outstanding | 267.52m |
Free float | 94.55m |
P/E (TTM) | 12.20 |
Market cap | 406.63m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 15 minutes, as of May 31 2024 07:15 BST.
More ▼